409 Development of ex vivo precision gene engineered B cell medicines that produce highly active and...
409 Development of ex vivo precision gene engineered B cell medicines that produce highly active and sustained levels of transgenic anti-tumor biologics
About this item
Full title
Author / Creator
Publisher
BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundBispecific T Cell Engagers (BiTEs), consisting of an anti-CD3 scFv fused to an anti-tumor antigen scFv, are highly effective in the treatment of relapsed/refractory Acute Lymphoblastic Leukemia (ALL). However, the short half-life of BiTEs necessitates continuous intravenous administration at high doses for four-week increments. To overcom...
Alternative Titles
Full title
409 Development of ex vivo precision gene engineered B cell medicines that produce highly active and sustained levels of transgenic anti-tumor biologics
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_e99d267b8a3846c3a680953b2c556131
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e99d267b8a3846c3a680953b2c556131
Other Identifiers
E-ISSN
2051-1426
DOI
10.1136/jitc-2023-SITC2023.0409
